Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Easy Way to Develop Drugs

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

One of the benefits to raking in $6.7 billion in free cash flow is that you can splurge a little if you don't feel like developing something in-house.

Such is the case with Merck (NYSE: MRK  ) getting into the follow-on biologics industry -- making copycat versions of biologic drugs -- which the company announced back in December. But bioreactors take time to build, and developing manufacturing processes for producing protein-based biologics isn't as simple as for small molecule drugs. So Merck has decided to go the easy route, and buy something that's already established.

The drugmaker is paying $130 million for Insmed's (Nasdaq: INSM  ) manufacturing facility and its follow-on biologics pipeline, including copycats of Amgen's (Nasdaq: AMGN  ) Neupogen and Neulasta. The drugs, which boost white blood cells in cancer patients, combined to bring in more than $4.6 billion in worldwide sales last year. That's no small potatoes, even if Merck will have to offer them at a discount.

Merck and Eli Lilly (NYSE: LLY  ) , which has also said it's interested in jumping into follow-on biologics, are behind other drugmakers like Teva Pharmaceutical (Nasdaq: TEVA  ) , Novartis (NYSE: NVS  ) , and Hospira (NYSE: HSP  ) that already have approvals in the European Union. The U.S. market is presumably larger, but Congress hasn't set up a system for the Food and Drug Administration to approve the follow-on biologics.

The purchase by Merck helps it catch up a little, and it should put the company in a good position to be able to submit a marketing application in the U.S., once the FDA starts accepting them. When it comes to revenue growth, Merck can certainly use all the help it can get.

More Foolishness:

Let us know what you think in Motley Fool CAPS. Make an outperform  or underperform call on these companies or post a pitch about whether you think companies will benefit from follow-on biologics. It's free. It's fun. And, it's Foolish.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 831749, ~/Articles/ArticleHandler.aspx, 10/4/2015 5:35:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,472.37 200.36 1.23%
S&P 500 1,951.36 27.54 1.43%
NASD 4,707.78 80.69 1.74%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/2/2015 3:59 PM
INSM $19.44 Up +1.04 +5.65%
INSMED, INC. CAPS Rating: ***
MRK $50.14 Up +0.77 +1.56%
Merck & Co., Inc. CAPS Rating: ****
AMGN $142.47 Up +2.24 +1.60%
Amgen CAPS Rating: ****
HSP $0.00 Down +0.00 +0.00%
Hospira, Inc. CAPS Rating: ***
LLY $87.52 Up +2.34 +2.75%
Eli Lilly & Co. CAPS Rating: ****
NVS $93.27 Up +1.37 +1.49%
Novartis CAPS Rating: ****
TEVA $60.06 Up +1.56 +2.67%
Teva Pharmaceutica… CAPS Rating: *****